Diabetic Nephropathy Market - Global Report on Diabetic Nephropathy to 2020

<strong>Diabetic</strong> <strong>Nephropathy</strong> <strong>Market</strong> - <strong>Global</strong> Study on Healthcare Cloud 

Computing : Asia to Witness Highest Growth by 2020 

Persistence <strong>Market</strong> Research 

<strong>Global</strong> <strong>Diabetic</strong> <strong>Nephropathy</strong> <strong>Market</strong> will 

reach $3,145.9 million in 2020: Persistence 

<strong>Market</strong> Research 

Persistence <strong>Market</strong> Research 1



Persistence <strong>Market</strong> Research Released New <strong>Market</strong> <strong>Report</strong> “<strong>Global</strong> <strong>Market</strong> Study on <strong>Diabetic</strong> 

<strong>Nephropathy</strong> <strong>Market</strong> – Asia to Witness Highest Growth by 2020,”.The global diabetic 

nephropathy market was valued at USD 2,262.2 million in 2014 and is expected to grow at a 

CAGR of 5.6% from 2014 to 2020, to reach an expected value of USD 3,145.9 million in 

2020. 

Browse the full <strong>Global</strong> <strong>Market</strong> Study on <strong>Diabetic</strong> <strong>Nephropathy</strong> <strong>Market</strong>: Asia to Witness 

Highest Growth by 2020 report at http://www.persistencemarketresearch.com/marketresearch/diabetic-nephropathy-market.asp 

<strong>Diabetic</strong> nephropathy is a disease of the kidney glomerulus and one of the most significant 

complications in terms of mortality and morbidity for patients with diabetes. <strong>Global</strong>ly, the 

diabetic nephropathy market is witnessing significant growth due to increasing prevalence of 

diabetes and obesity in different regions of the world. In addition, increasing R&D 

investments in drug discovery and development and raising awareness about diabetes and 

kidney-related disorders are also driving the growth of the market. However, stringent 

regulatory requirements and longer approval time for drugs as well as the lack of 

comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth 

of diabetic nephropathy market. The global diabetic nephropathy market is estimated at 

USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to 

reach USD 3,145.9 million in 2020. 

In North America, various government programs are spreading awareness about diabetes 

and related renal complications. For instance, the National Kidney Disease Education 

Program, one of the major programs organized by the U.S. government, for increasing 

awareness about the various kidney diseases. In addition, the number of diabetic patients 

are also increasing in the region; according to the SciELO Public Health, approximately 35 

million people were affected with diabetes mellitus in 2000 and this number is expected to 

reach 64 million by 2025 in North America. 

In Europe, rise in healthcare expenditure for diabetes treatment and increasing prevalence 

of diabetes in the various part of Europe is boosting the growth of the European diabetic 

nephropathy market. According to IDF, approximately 55.4 million people had diabetes in 

2010 and the number is expected to reach 66.5 million by 2030 in Europe. According to the 

IDF, healthcare expenditure for diabetes treatment was approximately USD 105.5 billion in 

2010 and is expected to reach USD 124.6 billion by 2030 in Europe. 

Asia represents the fastest growing region in the diabetic nephropathy market due to the 

rise in a diabetic population in various countries such as Japan and the Southeast Asian 

countries. According to the International Diabetes Federation (IDF), developing countries, 




such as India and China, are expected to have the highest number of diabetes mellitus 

patients compared to developed countries, such as the U.S. and Germany. 

Sanofi is one of the leading players in the diabetic nephropathy market. Other major players 

in diabetic nephropathy market include Eli Lilly and Company, Mitsubishi Tanabe Pharma 

Corporation, Novartis AG, Pfizer, Inc., Abbott Laboratories, AbbVie, Inc., Bayer AG, Merck & 

Co., Inc., Bayer AG and Reata Pharmaceuticals, Inc. 

The global diabetic nephropathy market is segmented as follows: 

<strong>Diabetic</strong> nephropathy market, by model of treatment 

 

Disease Modifying Therapies 

Angiotensin-Converting Enzyme Inhibitors 

Angiotensin Receptor Blockers 

Diuretics 

Calcium Channel Blockers 

Renin Inhibitors 

Connective Tissue Growth Factor Inhibitors 

Antioxidant Inflammation Modulator 

Monocyte Chemoattractant Proteins Inhibitor 

Endothelin-A Receptor Antagonist 

G Protein-Coupled Receptors 

<strong>Diabetic</strong> nephropathy market, by geography 

 

 

 

 

North America 

U.S. 

Canada 

Europe 

Germany 

France 

U.K. 

Asia 

Japan 

China 

India 

Rest of the World (RoW) 




<strong>Market</strong> History: 

<strong>Diabetic</strong> nephropathy is a disease of the kidney glomerulus and one of the most significant complications 

in terms of mortality and morbidity for patients with diabetes. <strong>Diabetic</strong> nephropathy is mainly characterized 

by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as 

macroalbuminuria. <strong>Global</strong>ly, the diabetic nephropathy market is witnessing significant growth due to rise 

in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D 

investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and 

Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory 

requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic 

management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. The 

global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a 

CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020. 

North America has the largest market for the global diabetic nephropathy market. However, In terms of 

growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest 

growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic 

nephropathy. 

North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0 

million in 2020, growing at a CAGR of 5.7% from 2014 to 2020. 

The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD 

2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020. 




Table of Content 

Chapter 1 Preface 

1.1 <strong>Report</strong> Description 

1.2 Research Methodology 

1.3 Assumptions 

Chapter 2 <strong>Market</strong> Synopsis 

Chapter 3 Porter’s Five Forces Analysis 

3.1 Bargaining Power of Suppliers 

3.2 Bargaining Power of Buyers 

3.3 Threat of New Entrants 

3.4 Threat of Substitutes 

3.5 Intensity of Rivalry 




Chapter 4 Industry Overview 

4.1 <strong>Market</strong> Definition 

4.2 <strong>Market</strong> Drivers 

4.2.1 Increasing prevalence of diabetes 

4.2.2 <strong>Global</strong>ly rising obesity increasing the prevalence of diabetes 

4.2.3 Increasing R&D investments in drug discovery and development 

4.2.4 Rising awareness among people about diabetes and kidney-related disorders 

4.3 Impact Analysis of <strong>Market</strong> Drivers 

4.4 <strong>Market</strong> Restraints 

4.4.1 Strict regulatory requirements and long approval time for drugs 

4.4.2 Lack of comprehensive therapeutic management for diabetic nephropathy 

4.5 Impact Analysis of <strong>Market</strong> Restraints 

4.6 <strong>Market</strong> Trends 

4.6.1 Increasing usage of combination therapy is gaining popularity in diabetic nephropathy 

market 

Chapter 5 <strong>Global</strong> <strong>Market</strong> Size and Forecast 

Chapter 6 <strong>Market</strong> Size and Forecast by Mode of Treatment 

6.1 Disease Modifying Therapies 

6.1.1 Angiotensin-Converting Enzyme Inhibitors 

6.1.2 Angiotensin Receptor Blockers 

6.1.3 Diuretics 

6.1.4 Calcium Channel Blockers 

6.1.5 Renin Inhibitors 

6.1.6 Connective Tissue Growth Factor Inhibitors 

6.1.7 Antioxidant Inflammation Modulator 

6.1.8 Monocyte Chemoattractant Proteins Inhibitor 

6.1.9 Endothelin-A Receptor Antagonist 

6.1.10 G Protein-Coupled Receptors 




Chapter 7 <strong>Market</strong> Size and Forecast by Geography 

7.1 North America 

7.1.1 Scenario in the U.S. 

7.1.2 Scenario in Canada 

7.2 Europe 

7.2.1 Scenario in Germany 

7.2.2 Scenario in France 

7.2.3 Scenario in the U.K. 

7.3 Asia 

7.3.1 Scenario in Japan 

7.3.2 Scenario in China 

7.3.3 Scenario in India 

Chapter 8 Pipeline Drugs for <strong>Diabetic</strong> <strong>Nephropathy</strong> 

8.1 Drugs Under Development for <strong>Diabetic</strong> <strong>Nephropathy</strong> 

Chapter 9 Competitive Scenario 

9.1 Competitive Benchmarking 

Chapter 10 Company Profiles 

10.1 Novartis AG 

10.1.1 Company overview 

10.1.2 Products and services 

10.1.3 Financial performance 

10.1.4 Key developments 

10.2 Merck & Co., Inc. 





10.3 Pfizer, Inc. 








10.4 Abbott Laboratories 





10.5 Sanofi 





10.6 Eli Lilly and Company 


10.6.2 Products and segments 



10.7 Reata Pharmaceuticals, Inc. 





10.8 Bayer AG 





10.9 AbbVie, Inc. 








10.10 Mitsubishi Tanabe Pharma Corporation 





List of Tables 

TABLE 1 <strong>Market</strong> Snapshot: <strong>Diabetic</strong> nephropathy market, 2014 and 2020 

TABLE 2 Drivers for diabetic nephropathy market: Impact analysis 

TABLE 3 Estimated average timelines for clinical trial approval in various countries 

TABLE 4 Restraints for diabetic nephropathy market: Impact analysis 

TABLE 5 <strong>Global</strong> diabetic nephropathy market size, by region, 2010 – 2013 (USD thousand) 

TABLE 6 <strong>Global</strong> diabetic nephropathy market size, by region, 2014 – 2020 (USD thousand) 

TABLE 7 <strong>Global</strong> diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD 

thousand) 

TABLE 8 <strong>Global</strong> diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD 

thousand) 

TABLE 9 <strong>Global</strong> DMT market size, by region, 2010 – 2013 (USD thousand) 

TABLE 10 <strong>Global</strong> DMT market size, by region, 2014 – 2020 (USD thousand) 

TABLE 11 <strong>Global</strong> DMT market size, by drug categories, 2010 – 2013 (USD thousand) 

TABLE 12 <strong>Global</strong> DMT market size, by drug categories, 2014 – 2020 (USD thousand) 

TABLE 13 <strong>Global</strong> ACE inhibitors market size, by region, 2010 – 2013 (USD thousand) 

TABLE 14 <strong>Global</strong> ACE inhibitors market size, by region, 2014 – 2020 (USD thousand) 

TABLE 15 <strong>Global</strong> ARBs market size, by region, 2010 – 2013 (USD thousand) 

TABLE 16 <strong>Global</strong> ARBs market size, by region, 2014 – 2020 (USD thousand) 

TABLE 17 <strong>Global</strong> diuretics market size, by region, 2010 – 2013 (USD thousand) 

TABLE 18 <strong>Global</strong> diuretics market size, by region, 2014 – 2020 (USD thousand) 

TABLE 19 <strong>Global</strong> CCBs market size, by region, 2010 – 2013 (USD thousand) 




TABLE 20 <strong>Global</strong> CCBs market size, by region, 2014 – 2020 (USD thousand) 

TABLE 21 <strong>Global</strong> renin inhibitors market size, by region, 2010 – 2013 (USD thousand) 

TABLE 22 <strong>Global</strong> renin inhibitors market size, by region, 2014 – 2020 (USD thousand) 

TABLE 23 <strong>Global</strong> CTGF inhibitors market size, by region, 2010 – 2013 (USD thousand) 

TABLE 24 <strong>Global</strong> CTGF inhibitors market size, by region, 2014 – 2020 (USD thousand) 

TABLE 25 <strong>Global</strong> AIM market size, by region, 2010 – 2013 (USD thousand) 

TABLE 26 <strong>Global</strong> AIM market size, by region, 2014 – 2020 (USD thousand) 

TABLE 27 <strong>Global</strong> MCP inhibitors market size, by region, 2010 – 2013 (USD thousand) 

TABLE 28 <strong>Global</strong> MCP inhibitors market size, by region, 2014 – 2020 (USD thousand) 

TABLE 29 <strong>Global</strong> ETAR market size, by region, 2010 – 2013 (USD thousand) 

TABLE 30 <strong>Global</strong> ETAR market size, by region, 2014 – 2020 (USD thousand) 

TABLE 31 <strong>Global</strong> GPCRs market size, by region, 2010 – 2013 (USD thousand) 

TABLE 32 <strong>Global</strong> GPCRs market size, by region, 2014 – 2020 (USD thousand) 

TABLE 33 The North American diabetic nephropathy market size, by country, 2010 – 2013 (USD 

thousand) 

TABLE 34 The North American diabetic nephropathy market size, by country, 2014 – 2020 (USD 

thousand) 

TABLE 35 The U.S. diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD 

thousand) 

TABLE 36 The U.S. diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD 

thousand) 

TABLE 37 The Canadian diabetic nephropathy market size, by mode of treatment, 2010 – 2013 

(USD thousand) 

TABLE 38 The Canadian diabetic nephropathy market size, by mode of treatment, 2014 – 2020 


TABLE 39 The European diabetic nephropathy market size, by country, 2010 – 2013 (USD 

thousand) 

TABLE 40 The European diabetic nephropathy market size, by country, 2014 – 2020 (USD 

thousand) 

TABLE 41 The German diabetic nephropathy market size, by mode of treatment, 2010 – 2013 





TABLE 42 The German diabetic nephropathy market size, by mode of treatment, 2014 – 2020 


TABLE 43 The French diabetic nephropathy market size, by mode of treatment, 2010 – 2013 


TABLE 44 The French diabetic nephropathy market size, by mode of treatment, 2014 – 2020 


TABLE 45 The U.K. diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD 

thousand) 

TABLE 46 The U.K. diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD 

thousand) 

TABLE 47 The Asian diabetic nephropathy market size, by country, 2010 – 2013 (USD 

thousand) 

TABLE 48 The Asian diabetic nephropathy market size, by country, 2014 – 2020 (USD 

thousand) 

TABLE 49 The Japanese diabetic nephropathy market size, by mode of treatment, 2010 – 2013 


TABLE 50 The Japanese diabetic nephropathy market size, by mode of treatment, 2014 – 2020 


TABLE 51 The Chinese diabetic nephropathy market size, by mode of treatment, 2010 – 2013 


TABLE 52 The Chinese diabetic nephropathy market size, by mode of treatment, 2014 – 2020 


TABLE 53 The Indian diabetic nephropathy market size, by mode of treatment, 2010 – 2013 


TABLE 54 The Indian diabetic nephropathy market size, by mode of treatment, 2014 – 2020 


TABLE 55 Major pipeline drugs for diabetic nephropathy 

TABLE 56 Product categories of Novartis AG 

TABLE 57 Product categories of Merck & Co., Inc. 

TABLE 58 Product categories of Pfizer, Inc. 

TABLE 59 Product categories of Abbott Laboratories 




TABLE 60 Product categories of Sanofi 

TABLE 61 Product segments of Eli Lilly and Company 

TABLE 62 Product categories of Reata Pharmaceuticals, Inc. 

TABLE 63 Product categories of Bayer AG 

TABLE 64 Product categories of AbbVie, Inc. 

TABLE 65 Product categories of Mitsubishi Tanabe Pharma Corporation 

List of Figures 

FIG. 1 <strong>Diabetic</strong> nephropathy market: Porter’s five forces analysis 

FIG. 2 Major DMT for diabetic nephropathy 

FIG. 3 Number of people with diabetes mellitus (20 – 79 years) in major countries, 2010, and 

2030 (million) 

FIG. 4 Prevalence of overweight and obese males aged 30 years and above, 2005 and 2015 

(%) 

FIG. 5 Prevalence of overweight and obese females aged 30 years and above, 2005 and 2015 

(%) 

FIG. 6 <strong>Global</strong> diabetic nephropathy market share, by region, by value, 2013 

FIG. 7 <strong>Global</strong> diabetic nephropathy market share, by mode of treatment, by value, 2013 

FIG. 8 <strong>Global</strong> DMT market share, by region, by value, 2013 30 

FIG. 9 <strong>Global</strong> DMT market share, by disease categories, by value, 2013 

FIG. 10 <strong>Global</strong> ACE inhibitors market share, by region, by value, 2013 

FIG. 11 <strong>Global</strong> ARBs market share, by region, by value, 2013 

FIG. 12 <strong>Global</strong> diuretics market share, by region, by value, 2013 

FIG. 13 <strong>Global</strong> CCBs market share, by region, by value, 2013 

FIG. 14 <strong>Global</strong> renin inhibitors market share, by region, by value, 2013 

FIG. 15 <strong>Global</strong> CTGF inhibitors market share, by region, by value, 2013 

FIG. 16 <strong>Global</strong> AIM market share, by region, by value, 2013 

FIG. 17 <strong>Global</strong> MCP inhibitors market share, by region, by value, 2013 

FIG. 18 <strong>Global</strong> ETAR market share, by region, by value, 2013 

FIG. 19 <strong>Global</strong> GPCRs market share, by region, by value, 2013 

FIG. 20 The North American diabetic nephropathy market share, by country, by value, 2013 




FIG. 21 The U.S. diabetic nephropathy market share, by mode of treatment, by value, 2013 

FIG. 22 The Canadian diabetic nephropathy market share, by mode of treatment, by value, 

2013 

FIG. 23 The European diabetic nephropathy market share, by country, by value, 2013 

FIG. 24 The German diabetic nephropathy market share, by mode of treatment, by value, 2013 

FIG. 25 The French diabetic nephropathy market share, by mode of treatment, by value, 2013 

FIG. 26 The U.K. diabetic nephropathy market share, by mode of treatment, by value, 2013 

FIG. 27 The Asian diabetic nephropathy market share, by country, by value, 2013 

FIG. 28 The Japanese diabetic nephropathy market share, by mode of treatment, by value, 

2013 

FIG. 29 The Chinese diabetic nephropathy market share, by mode of treatment, by value, 2013 

FIG. 30 The Indian diabetic nephropathy market share, by mode of treatment, by value, 2013 

FIG. 31 Competitive landscape of diabetic nephropathy market, 2013 

FIG. 32 Novartis AG’s net sales and net income, 2011 – 2013 (USD million) 

FIG. 33 Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million) 

FIG. 34 Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million) 

FIG. 35 Abbott Laboratories’ net sales and net earnings, 2011 – 2013 (USD million) 

FIG. 36 Sanofi’s net sales and net income, 2011 – 2013 (USD million) 

FIG. 37 Eli Lilly and Company’s revenue and net income, 2011 – 2013 (USD million) 

FIG. 38 Bayer AG’s net sales and net income, 2011 – 2013 (USD million) 

FIG. 39 AbbVie, Inc.’s net sales and net earnings, 2011 – 2013 (USD million) 

FIG. 40 Mitsubishi Tanabe Pharma Corporation’s net sales and net earnings, 2011 – 2013 (USD 

million) 

About Us: 

Persistence <strong>Market</strong> Research is a global market research firm specializing- syndicated research, 

custom research, and consulting services 

At Persistence <strong>Market</strong> Research (PMR), we are in the business of accelerating your business. As a fullservice 

market research firm, we stand committed to bringing more accuracy and speed to your business 

decisions. From ready-to-purchase market research reports to customized global research solutions, our 

engagement models are highly flexible without compromising on our deep-seated research values. Briefly 




stated, our mission is to give you access to forecasts and trends analyses that put you on the path to 

profitability. 

PMR’s Services Go Beyond Gleaning Data 

Most enterprises believe that IT and databases are enough to make an accurate decision. While we do 

not dispute that, consider this: How long does it take to make an accurate and strategic million-dollar 

decision? We strive to deliver both even with demanding deadlines. 

Contact Us: 

Addie Thomes 

305 Broadway 

7th Floor, New York City, 

NY 10007, United States, 

USA - Canada Toll Free: 800-961-0353 

Email: sales@persistencemarketresearch.com 

Web: http://www.persistencemarketresearch.com 

Twitter: https://twitter.com/addiethomes 

Blog: http://persistencemarketresearchblog.wordpress.com/

Diabetic Nephropathy Market - Global Report on Diabetic Nephropathy to 2020

Create successful ePaper yourself

Delete template?

Save as template?